A proof-of-mechanism trial in asthma with lunsekimig, a bispecific nanobody® molecule

Background Monovalent biologics blocking thymic stromal lymphopoietin or interleukin-13 have been shown to elicit pharmacodynamic responses in asthma following a single dose. Therefore, dual blockade of these cytokines may result in an enhanced response compared to single targeting and has the potential to break efficacy ceilings in asthma. This study assessed the safety and tolerability of lunsekimig, a bispecific NANOBODY ® molecule that blocks thymic stromal lymphopoietin and interleukin-13, and its effect on Type 2 inflammatory biomarkers and lung function in asthma. Methods This was a Phase 1b, single-dose (subcutaneous lunsekimig 400 mg or placebo), randomised (2:1), double-blind, proof-of-mechanism study in 36 participants with mild-to-moderate asthma and elevated fractional exhaled nitric oxide (≥25 ppb), a marker of airway inflammation. The primary endpoint was safety and tolerability through Day 71. The main pharmacodynamic secondary endpoint was change from baseline in fractional exhaled nitric oxide at Day 29. Results Lunsekimig was well tolerated, with no serious treatment-emergent adverse events. Fractional exhaled nitric oxide was significantly reduced from Day 8 through Day 29 after a single dose, with change from baseline of −40.9 ppb (90% CI: −55.43 to −26.39; p<0.0001) versus placebo at Day 29. Blood-based Type 2 biomarkers at Day 29 were significantly reduced from baseline. Lung function, particularly small airway dysfunction, was numerically improved at Day 29, most notably in participants with impaired lung function at baseline. Conclusions A single dose of lunsekimig was well tolerated, significantly suppressed Type 2 inflammation, and improved lung function in mild-to-moderate asthma.